Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation, the Company's need for additional capital which may not be available in a timely manner or at all and which, if not obtained, will have a material adverse impact on the Company and its ability to continue; the impact of the global economic downturn and credit crisis which have negatively affected the availability and terms of debt and equity financings and may have a negative effect on our sales operations and research and development initiatives; uncertainty whether an Investigational New Drug application ("IND") or Clinical Trial application ("CTA") will be compiled or submitted for Topical Interferon Alpha-2b or L-DOS47 as currently planned or at all, or if submitted, whether the Company will be permitted to undertake human testing; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; uncertainty whether the planned Topical Interferon Alpha-2b Phase IIb / III clinical trials, the human pharmacokinetic study, the ongoing AGW clinical trial in Sweden and Germany, or the planned L-DOS47 clinical trial referred to in this news release will be approved or initiated, in the case of Topical Interferon Alpha-2b and L-DOS47, or will be completed as planned, within the time frames expected by the Company, or at all or will achieve expected results; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, including the possibility that further challenges may arise in connection with the manufacture of clinical batches of L-DOS47 or Topical Interferon Alpha-2b which could further delay or otherwise negatively affect the Company's planned IND filings and clinical trials, and the risk of obtaini
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... BerGenBio AS ("BerGenBio" or the ... abstract on the latest data on BGB324, the Company,s ... tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody ... conjunction with the 2015 American Society of Clinical Oncology ... May 29 - June 2, 2015. The ...
(Date:5/29/2015)... The Academy of Model Aeronautics has ... graduates from across the nation. , The Academy of ... AMA Youth Members with scholarships to pursue technical careers. ... has awarded nearly $900,000 to college-bound aero-modelers. The scholarships ... and individuals, AMA member donations, a portion of AMA ...
(Date:5/29/2015)... May 29, 2015 Market Publishers ... ) signed a partnership agreement for quality market ... to distribute and sell research reports worked out ... Partners Department, commented upon the agreement: “Chem-Report is ... key petroleum and chemical markets on global and ...
(Date:5/29/2015)... When a leading manufacturer of ... to design an industrial oven that ... being produced using a 3D-printing process, Gruenberg engineers ... gantry, heat-saving windows, and internal actuators and sensors ... pills to exact specifications. , To ensure the ...
Breaking Biology Technology:BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Academy of Model Aeronautics Awards $46,500 in Scholarships to College-Bound Model Aviation Pilots 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2
... Technology Can Solve Pressing Food, Fuel Problems of ... ON, Dec. 3 /PRNewswire/ - Dr. David Dennis, FRSC, CEO of ... at a side event at the United Nations Climate Change Conference ... solved global problems in the 20th Century and the role it ...
... DEERFIELD, Ill., Dec. 3 Today, the International Society,for ... stem cell researchers, released new guidelines for the responsible,development ... A,Commentary article that summarizes the Guidelines for the ... Press in the December issue of Cell,Stem Cell, the ...
... VIENNA, Va., Dec. 3 In response to numerous,shareholder ... it has added updated pictures of it new manufacturing ... CEL-SCI,s homepage,( http://www.cel-sci.com ) by clicking on the link ... , CEL-SCI is ...
Cached Biology Technology:Leading Canadian Scientist to speak at UN Climate Change Conference 2The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 2The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 3The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy 4
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... - Coding variants in immune disease-related genes play only ... psoriasis, according to a new study led by Anhui ... by their investigation on the contribution of functional coding ... a large-scale investigation, researchers only discovered two independent low-frequency ...
... Baltimore, MD November 9, 2013 New research ... Americans with chronic kidney disease contribute to a more ... The research, led by investigators from the University of ... help explain, in part, why even after accounting for ...
... other devices that can change shape or move with ... may be possible through research led by the University ... when triggered by light, thereby converting light energy into ... machine components such as switches and power sources. ...
Cached Biology News:The contribution of coding variants to psoriasis much smaller than thought 2Genetic variation increases risk of kidney disease progression in African-Americans 2Genetic variation increases risk of kidney disease progression in African-Americans 3Genetic variation increases risk of kidney disease progression in African-Americans 4Snap to attention: Polymers that react and move to light 2
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
DONOR BOVINE SERUM AND PLASMA...
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: